Treatment of cells with cisplatin induces a sustained activation of the stress activated protein kinase SAPK/ JNK and the mitogen-activated protein kinase p38. Activation of JNK by cisplatin is necessary for the induction of apoptosis. Expression of the MAPK phosphatases CL100/MKP-1 and hVH-5 selectively prevents JNK/SAPK activation by cisplatin in a dose dependent fashion and results in protection against cisplatin-induced apoptosis. In contrast, expression of the ERK-speci®c phosphatase Pyst1 inhibits JNK/SAPK activity only when expressed at very high levels and does not confer protection against cisplatin. Furthermore, expression of a catalytically inactive mutant of CL100 in 293 cells decreases the IC 50 for cisplatin and increases the toxicity of transplatin. This eect seems to be mediated by an increase in JNK activity since p38 activity is unaected. These results suggest that dualspeci®city MAPK phosphatases may be candidate drug targets in order to optimize cisplatin based therapeutic protocols. Oncogene (2000) 19, 5142 ± 5152.
Introduction
Stress stimuli that induce apoptosis, including UV-and g-irradiation, heat shock, protein synthesis inhibitors, DNA-damaging agents and the proin¯ammatory cytokines tumor necrosis factor a and interleukin-1, are potent activators of SAPK1/JNK. Several antineoplastic agents such as cisplatin, etoposide, camptothecin and taxol which are also strong inducers of apoptosis, also activate the SAPK1 pathway (Seimiya et al., 1997) . Certain of these stimuli activate both JNK and p38 (SAPK2) but their speci®c role in triggering the apoptotic program remains unclear. Expression of constitutively activated forms of components of the JNK pathway such as ASK1, a mammalian MAPKKK (Ichijo et al., 1997) , and also MEKK1 (Johnson et al., 1996) cause lethality in ®broblasts. Furthermore, expression of dominant negative mutants of either MEKK1 or SEK1 blocks apoptosis induced by UV-C and g-radiation (Chen et al., 1996b) , cisplatin (SaÂ nchez-PeÂ rez and Perond, 1999) and NGF withdrawal (Xia et al., 1995) supporting the role of this cascade in apoptotic responses.
A considerable body of evidence in the literature indicates that both the magnitude and duration of MAPK activation have an important eect on the determination of cell fate. In PC12 cells the transient induction of MAPK/ERK activity promotes cell proliferation, whereas prolonged activation of MAPK/ERK drives cells into neuronal dierentiation (Marshall, 1995) . Furthermore, JNK activation induced by PMA in Jurkat cells results in either cell proliferation or apoptosis depending on whether activation is transient or sustained (Chen et al., 1996a) . This suggests that the enzymes involved in inactivation of MAPK activity play a crucial role in cell fate decisions in response to external stimuli. MAPK and JNK/SAPK activation requires phosphorylation of both threonine and tyrosine residues in a conserved T-X-Y motif (DeÂ rijard et al., 1994; Hibi et al., 1993; Kyriakis et al., 1994) . These residues are dephosphorylated by protein phosphatases resulting in inactivation of MAP kinases. A growing family of dual-speci®city MAPK phosphatases have been identi®ed (Keyse, 1995) . These include VHR (Ishibashi et al., 1993) , CL100 (MKP-1) Keyse et al., 1992; Noguchi et al., 1993) , Pac1, (Rohan et al., 1993) MKP-2 (hVH2, TYP-1) (Guan and Buth, 1995; King et al., 1995; Misra-Press et al., 1995) , hVH-3 (B23) (Ishibashi et al., 1994; Kwak et al., 1994) , hVH-5 (M3/6) (Martell et al., 1995; Theodosiou et al., 1996) , MKP-3 (Pyst1, rVH6), Pyst2 (Groom et al., 1996; Muda et al., 1996) . MKP-4 (Muda et al., 1997) and MKP-5 (Tanoue et al., 1999) . MKP-1/CL100, the ®rst member of this family to be identi®ed as an ERK speci®c phosphatase, is also able to inactivate SAPK and p38 MAPK (Chu et al., 1996; Franklin and Kraft, 1995; Gupta et al., 1996; Liu et al., 1995; and both MKP-1/CL100 and hVH-5 have been shown to be more active towards JNK and p38 than towards the`classical' ERK1 and 2 MAP kinases (Franklin and Kraft, 1997; Muda et al., 1996) . In contrast, Pyst1 a recently identi®ed member of this family of phosphatases is capable of inactivating ERKs very eciently but has a very low activity against JNK and p38 (Groom et al., 1996) .
Cisplatin is a DNA reactive molecule widely used as a chemotherapeutic drug in the treatment of several kinds of human malignancies (Mello et al., 1995) . In contrast, transplatin, the trans isomer of this drug, is ineective against tumors (Pinto and Lippard, 1985) . We have found that transplatin induces a transient activation of JNK whereas cisplatin treated cells show a persistence of activation of this kinase. The kinetics of JNK activation induced by transplatin can be prolonged by pretreatment of cells with orthovanadate, a tyrosine phosphatase inhibitor. This positive modulation of JNK activation correlates with an increase by an order of magnitude in the toxicity of both transplatin and cisplatin (SaÂ nchez-PeÂ rez et al., 1998) . Furthermore, we have found that transplatin eciently induces MKP-1/CL100, and its expression correlates temporally with JNK inactivation. In contrast, cisplatin is only a very weak inducer of MKP-1/ CL100. These results suggest that the persistent activation of JNK in response to cisplatin may be due to its inability to induce the expression of this phosphatase. In this study, we have exploited the ability of MKP-1/CL100 and hVH-5 to speci®cally dephosphorylate JNK, in order to examine whether inhibition of JNK activity would provide protection against cisplatin. Expression of MKP-1/CL100 and hVH-5, but not Pyst1, inhibits JNK and p38 activation after cisplatin treatment. Expression of MKP-1/CL100 and hVH-5 also correlates with an increase in survival after treatment with cisplatin. Moreover ectopic expression of a catalytically inactive mutant of MKP-1/CL100 in 293 cells increases cell death in response to both cisplatin and transplatin. The results suggest that inhibition of MKP-1/CL100 activity in tumor cells might improve the therapeutic response to cisplatin in human cancer.
Results
Expression of CL100 and hVH-5 prevents JNK activation by cisplatin
We have previously described that cisplatin induces an increase in JNK activity with a persistent kinetic, in several cell types. This kinetic seems to correlate with a reduced expression of MKP-1, in contrast to what occurs with transplatin, which induces a transient kinetic and elevated expression of MKP-1 (SaÂ nchezPeÂ rez et al., 1998). We have studied whether expression of the human homolog of MKP-1, CL100 could block cisplatin induced activation of JNK in 293T cells. To this end, 293T cells were transiently transfected with dierent doses of either the CL100 expression vector carrying the myc tagging epitope and, in parallel, the empty vector, and further treated with cisplatin. We used GST-jun (1 ± 79) bound to GSH-sepharose beads to precipitate endogenous JNK activity after treatment of 293T cells. The obtained results of the measurement of JNK activity indicate ( Figure 1a ) that expression of the CL100 vector did not aect basal JNK activity at any of the doses used, maybe because this background activity is due to an unknown kinase insensitive to CL100. On the other hand transfection of 1 mg of CL100 was able to reduce JNK activation by more than 50%. Maximal inhibition was obtained at the dose of 2.5 mg of plasmid. Thus, these results indicate that inhibition of JNK activation by cisplatin is Figure 1 Eect of CL100 expression on JNK and p38 activation by cisplatin. 293T cells were transiently transfected with the indicated amounts of c-myc-CL100 expression vector. Cells were then serum depleted for 24 h and treated with cisplatin (20 mg/ml) for 6 h. Activity was measured in cell extracts by using agarose beads coupled with puri®ed GST-c-jun or immunocomplexes with puri®ed GST-ATF-2 fusion proteins respectively. In (a) and (b) the graphic shows the relative incorporation obtained in a typical experiment where the radioactivity present in each line (shown in lower panel) was measured in an instantimager. The amount incorporated in the samples transfected with the plasmid vector was considered as 100. The experiment was repeated twice with similar results. (c) Western blot analysis of c-myc-CL100 expression in the extracts used in (a) and (b) dependent on expressed CL100 in a dose dependent manner (Figure 1c) .
The pro®le of activation of both JNK and p38 in 293T cells in response to cisplatin is similar (SaÂ nchezPeÂ rez and Perona, 1999 ). Since CL100 is also able to dephosphorylate p38 (Franklin and Kraft, 1997; Groom et al., 1996) we sought to investigate whether the expression of CL100 inhibits p38 activation by cisplatin in this cell system. The results (Figure 1b) indicate that expression of CL100 does inhibit activation of p38 by cisplatin. As a control, complete inhibition was observed in extracts of stimulated cells treated with the p38 inhibitor SB203580.
Similar studies were performed with the dual speci®c phosphatase Pyst1 to determine if inhibition of JNK activation by CL100 was really dependent on substrate speci®city. Pyst1 has been shown to dephosphorylate both ERK1 and 2 but not JNK or p38 (Groom et al., 1996) . The results presented in Figure 2a indicate that expression of Pyst1 not only does not inhibit activation of JNK by cisplatin but can induce a slight increase in activity. Only at higher doses of transfected plasmid (5 mg of DNA) is a small inhibition of cisplatin dependent JNK activation observed (Figure 2a ). In contrast, the IC 50 for inhibition of JNK activity by CL100 is less than 1 mg of DNA. We performed the same type of experiment and assayed the extracts for p38 activity. The results (Figure 2b ) clearly show that p38 activity is also only weakly inhibited by expression of Pyst1. Since cisplatin does not eciently induce activation of ERKs we stimulated 293T cells with EGF in order to test for the functionality of the expressed Pyst1. The results demonstrate that activation of both ERK1 and 2 was inhibited in a dose dependent manner after expression of Pyst1 (Figure 2c ).
hVH-5 is a relatively new member of the dual speci®c phosphatase family that is induced upon treatment of neuronal cells with growth factors Martell et al., 1995) . Although little is known about the physiological role of hVH-5 the enzyme has been reported to speci®cally inactivate JNK and p38 MAP kinases (Muda et al., 1996) . We studied the eect of ectopic expression of hVH-5 on the activation of JNK or p38 in response to cisplatin. The results show that expression of hVH-5 strongly inhibited activation of JNK ( Figure 3a ) and p38 in response to cisplatin (Figure 3b ). hVH-5 was equally potent against both kinases with an ID 50 of 0.5 mg of plasmid. This is in the same range as the potency of MKP-1/CL100 for JNK and p38 dephosphorylation.
CL100 and hVH-5 form a physical complex in vivo with JNK
Previous results have indicated that wild type Pyst1 is able to dephosphorylate and form stable complexes with ERKs (Groom et al., 1996) . In contrast, CL100 is Figure 2 Eect of Pyst1 expression on JNK and p38 activation by cisplatin. 293T cells were transiently transfected with the indicated amounts of c-myc-Pyst1 expression vector. Cells were then serum depleted for 24 h and treated with cisplatin (20 mg/ml) during 6 h. Activity was measured in cell extracts by using agarose beads coupled with puri®ed GST-c-jun or immunocomplexes with puri®ed GST-ATF-2 fusion proteins respectively. In (a) and (b) the graphic shows the relative phosphorylation obtained in a typical experiment where the incorporation of radioactivity in each line (lower panel) was measured in an instantimager. The amount incorporated in the samples transfected with the plasmid vector was considered as 100. The experiment was repeated twice with similar results. (c) Inactivation of p42/44MAPK by Pyst1. 293T cells were transfected with dierent doses of DNA. After transfection cells were incubated for 16 h in serum-free medium and stimulated with 20 ng/ml EGF during 5 min. Activated MAPK was detected in Western blots using a speci®c antibody for phospho p42/44MAPK. (d) Western blot analysis of c-myc-Pyst1 expression in the extracts used in (a) and (b) only able to form a stable complex with ERK2 when it carries a mutation of the active site cysteine to serine (Groom et al., 1996; Sun et al., 1993) . In view of our results showing that both MKP-1/CL100 and hVH-5 are more potent towards JNK than against ERKs, we have examined whether the activity of these phosphatases towards JNK correlates with the formation of complexes between these enzymes. Cotransfections of either the empty vector or myc-tagged forms of one of the three phosphatases together with HA-epitope tagged JNK were carried out in 293T cells. Unstimulated or cisplatin stimulated cells were immunoprecipitated with the anti-HA 12CA5 monoclonal antibody and then subjected to Western blotting using an antimyc antibody. The results showed that wild-type CL100 and hVH-5 form stable complexes in vitro with JNK ( Figure 4 ). In contrast, Pyst1 was not able to form complexes with JNK1 under the same experimental conditions, although it was expressed at similar levels to CL100 and hVH-5 (Figure 4 ).
CL100 and hVH-5 inhibit c-Jun dependent transcription after cisplatin treatment
We have previously shown that activation of JNK and apoptosis induced by cisplatin are mediated by the MEKK1/SEK1 cascade (SaÂ nchez-PeÂ rez and Perona, 1999) . Since both CL100 and hVH-5 are able to inactivate JNK after cisplatin treatment, we sought to elucidate the physiological role of these phosphatases in cells in which the MEKK1/SEK cascade has been activated. A consequence of the activation of the JNK/ SAPKs is the stimulation of the transcriptional activity of c-Jun (Kyriakis et al., 1994) . Thus transcriptional activation of c-Jun was assayed after cotransfection of the MEKK1 gene along with the three phosphatase genes and the c-Jun dependent transcription reporter system described in Materials and methods ( Figure 5 ). The results strongly show that expression of either CL100 or hVH-5 inhibit c-Jun dependent transcription. Conversely, expression of Pyst1 not only does not inhibit c-Jun activation, but it can stimulate transcription at low doses. This is in agreement with our results obtained on JNK activity in Pyst1 expressing cells ( Figure 2a ).
CL100 but not Pyst1 protects cells from apoptosis induction by cisplatin
We have previously published that constitutive activation of JNK correlates with induction of apoptosis in response to cisplatin (SaÂ nchez-PeÂ rez et al., 1998). We then tested whether the expression of the dierent phosphatases has any eect on cell death in response to this drug. 293T cells were transfected with either CL100, Pyst1 or hVH-5, treated with cisplatin and dead cells were identi®ed by DAPI staining (Figure 6a ). Cells transfected with the control vector or Pyst1 exhibited an apoptotic phenotype after cisplatin treatment in most of the ®elds examined (Figure 6b ). In contrast, expression of CL100 or hVH-5 provided protection against apoptosis induced by cisplatin and cells retained normal nuclear morphology. Ectopic expression of CL100 in 293T cells induces a reduction Figure 3 Eect of hVH-5 expression on JNK and p38 activation by cisplatin. 293T cells were transiently transfected with the indicated amounts of c-myc h-VH5 expression vector. Cells were then serum depleted for 24 h and treated with cisplatin (20 mg/ml) for 6 h. Activity was measured in cell extracts by using agarose beads coupled with puri®ed GST-c-jun or immunocomplexes with puri®ed GST-ATF-2 fusion proteins respectively. In Figure 4 CL100 and hVH-5 are able to form physical complexes with JNK1. Cells were cotransfected with the plasmid vector (pSG5) or expression vectors containing either myc-CL100, mycPyst1, or myc-hVH-5, and HA-JNK1. Cells were either left unstimulated (minus sign) or cisplatin stimulated for 4 h (plus sign) before immunoprecipitation using anti-HA monoclonal antibody. The dierent phosphatases were then detected in these immunoprecipitates using an anti-Myc polyclonal antibody. Samples corresponding to 10% of the extracts from unstimulated cells were also analysed directly for phosphatase expression by immunoblotting with anti-Myc as a control (Figure 6c ). Taken together, our results suggest that CL100 and hVH-5 could block cisplatin induced apoptosis by inhibiting activation of JNK and/or p38.
Expression of a dominant negative mutant of CL100 sensitizes cells to cis and transplatin Our observation that expression of CL100 inhibits JNK activation and apoptosis induced by cisplatin suggests that dierent expression levels of CL100 could be important for the regulation of apoptosis. In order to test this hypothesis we obtained a catalytically inactive mutant of CL100 (Cys 258 to Ala) by site directed mutagenesis. The mutation Cys258Ser has been shown to code for an inactive enzyme in both CL100 and its mouse homolog MKP-1 (Alessi et al., 1993; Sun et al., 1993) . Expression of CL100 (C258A) tagged with a myc epitope in 293T cells (Figure 7a ) resulted in a greater induction of c-Jun phosphorylation in response to cisplatin, indicating a stronger activation of JNK (Figure 7b ). Moreover, treatment of cells expressing this mutant form of CL100 with transplatin induces a prolonged rather than a transient activation of JNK that goes on for at least 8 h ( Figure  7c ).
As indicated in Figure 1 expression of CL100 was also able to inhibit activation of p38 in response to cisplatin. We tested the eect of expressing the CL100 (C258A) plasmid on p38 activity after treatment with both platinum isomers. In contrast with the results obtained with c-Jun phosphorylation, p38 activation was not aected by the expression of this mutant (Figure 7b,c) . The only dierence observed in response to transplatin was the earlier activation of p38 in CL100 (C258A) expressing cells, but no change in the level of activation was observed. These results indicate that endogenous CL100 regulated JNK activation by both platinum isomers and that p38 activity was not regulated by this phosphatase. We have also checked for the eect on ERKs activity of expression of the CL100 mutant in cells after cisplatin or EGF treatment (Figure 7d ). In this system cisplatin did not activate ERK up to 6 h after treatment, as previously described for other cell types (SaÂ nchez-PeÂ rez et al., 1998), neither aected ERK activation in response to EGF. Alto- Figure 7 Eect of CL100 (C258A) expression on JNK, p38 and ERK activation by cisplatin. (a) Western blot of cells transfected with CL100 (C258A). Cells were transfected with dierent doses of myc-tagged CL100 (C258A) and immunoblotted with anti c-myc. (b) and (c) JNK and p38 activity in cells treated with transplatin and cisplatin. Cells were transfected with 3 mg of pSG5 or pSG5-CL100 (C258A) incubated in serum free medium and exposed to c-DDP or t-DDP (20 mg/ml) and UV as a control for p38 activation. Samples were collected at the indicated time periods after treatment and subjected to SDS electrophoresis. Filters were immunoblotted with anti phospho-c-Jun, anti phospho p38 for analysis of JNK and p38 activities or anti p38 antibody for expression of p38. (d) ERK activity in cells treated with cisplatin (20 mg/ml) or EGF (20 ng/ml). Cells were transfected as in (b) and (c), incubated in serum free medium and exposed to EGF or c-DDP. Samples were collected at the indicated time periods after treatment and subjected to SDS electrophoresis. Filters were immunoblotted with anti-phospho p42/44MAPK for ERK's activity and anti ERK2 for expression of ERK Oncogene Modulation of cisplatin induced apoptosis by CL100/MKP-1 I Sanchez-Pe Â rez et al gether these results suggest that expression of the inactive mutant of CL100 blocks the activity of endogenous CL100 and results in a prolonged and more ecient activation of JNK.
The results obtained previously strongly show that expression of CL100 inhibits c-Jun dependent transcription. We tested the eect of expressing the CL100 (C258A) mutant on this parameter by cotransfection of the MEKK1 gene along with the mutant CL100 expression vector and using the system described in Materials and methods. The results show (Figure 8 ) that c-Jun dependent transcription increases in a dose dependent manner by expression of the CL100 (C258A) gene. These results also indicate that the expression of the mutant gene does not block the interaction of activated JNK with its substrates (Figure  7b ,c) allowing an enhancement in their phosphorylation.
As expression of CL100 (C258A) induces upregulation of JNK activity in response to both platinum isomers we tested the eect on cell viability. We obtained stable 293T transfectants expressing the CL100 (C258A) gene ( Figure 9a ) and studied their sensitivity to cisplatin. After treatment of control (pSG5 transfected) and CL100 (C258A) expressing cells with cisplatin we found an increase in sensitivity of cells expressing the mutated version of CL100, that was of 25-fold when compared to control cells (Figure 9b) . Moreover, we also found an increase of sensitivity in CL100 (C258A) expressing cells also to transplatin (15-fold). In order to make sure that this eect was not cell-type speci®c, we infected Pam212 cells with retroviruses expressing either CL100 or CL100 (C258A) (Figure 9c ) and tested the eect of transplatin treatment on activation of JNK and c-Jun phosphorylation ( Figure 9d ). As shown for 293T cells (Figure  7b,c) , both JNK activation and c-Jun phosphorylation was prolonged in response to the drug in CL100 (C258A) infected cells (Figure 9d ). By contrast in cells infected with CL100, JNK activation and in consequence c-Jun phosphorylation was inhibited, after transplatin treatment. Similar results were obtained in response to cisplatin (data not shown) as observed earlier (Figures 1a and 7b) . When we tested for viability, we found that expression of the CL100 induced a decrease in sensitivity to cisplatin, as observed for 293T cells ( Figure 6 ) and also to transplatin (Figure 9e ). On the contrary, expression of the CL100 (C258A) mutant increases the sensitivity to both platinum isomers (Figure 9e ) in a similar magnitude than seen in 293T cells. Altogether these results suggest that endogenous CL100 plays an important role in controlling JNK and cell death activation in response to platinum compounds.
Discussion
A large number of publications in recent years have implicated MAPKs in the regulation of a wide variety of physiological processes in response to hormones, growth factors and stress (Marshall, 1994; Nishida et al., 1993) . MAPK activation by dierent stimuli is often transient in nature, even during prolonged exposure to the agonist. Furthermore, this process is tightly controlled by the balance of the MAPK kinase and MAPK phosphatase activities. Recently much emphasis has been placed on the role of JNK and p38 in the induction of apoptosis in dierent cell systems in the context of several types of cellular stress (Hibi et al., 1993; Kharbanda et al., 1995; Kyriakis et al., 1994 ). Yet, little is known about the physiological role(s) of MAPK phosphatases in regulating these events.
We have previously reported the persistent activation of JNK in response to cisplatin which seems to correlate inversely with the level of expression of the MAPK phosphatase MKP-1 (SaÂ nchez-PeÂ rez et al., 1998). On the other hand, transplatin very eciently induces expression of MKP-1, and this expression correlates with the weak and transient activation of JNK by this agent. These results suggested that dierences in expression levels of members of the dual speci®city MAPK phosphatase family could be involved in the regulation of JNK or p38 activity in response to stress. In this study we have demonstrated that expression of two dierent MAPK phosphatases, CL100 and hVH-5, is able to inhibit activation of JNK and p38 activities in response to cisplatin.
Inactivation of JNK and p38 by expression of either CL100 or hVH-5 blocks downstream signaling from the MAPK. Both phosphatases are able to inhibit transcriptional activation of c-Jun, the main physiological substrate of JNK (Kyriakis et al., 1994) . We have previously shown that c-Jun is necessary for apoptosis induction in response to cisplatin since a cell-line derived from a c-jun knock-out mouse is more resistant than normal cells to cisplatin induced cell death. This eect is speci®c since transfection of c-jun into this cJun7/7 cell-line, thereby restoring its endogenous activity, results in a phenotype similar to that of parental cells (SaÂ nchez-PeÂ rez and Perona, 1999) . This is in agreement with previous reports that expression of c-Jun in NIH3T3 cells induces apoptosis after serum deprivation (Bossy-Wetzel et al., 1997) . These studies suggest that AP-1 complexes may activate the transcription of death genes in response to cisplatin. Recently, it has been reported that Fas-ligand (Fas-L) is induced by an AP-1-dependent mechanism in response to DNA damage. Activation of Fas-L transcription also correlates with induction of JNK activity and consequent phosphorylation of c-Jun (Kasibhatla et al., 1998) . Hence, Fas-L may be a death gene target whose transcription is activated by cJun in response to cisplatin. The inhibition of c-Jun dependent transcription induced by expression of CL100 and hVH-5, correlates with an increase in survival after exposure to cisplatin. In contrast, expression of a third member of this family, Pyst1, after cisplatin treatment has no eect on the regulation of JNK or p38 activation and therefore in cell death. In agreement with these results, recently it has been reported that ectopic expression of MKP-1 results in protection against UVC-induced cell death (Franklin et al., 1998) . However, the role for endogenous MAPK phosphatases in the regulation of cell death is still unclear.
MAPK phosphatases have been found to form complexes in vivo with their target kinases and to subsequently dephosphorylate them (Groom et al., 1996; Tanoue et al., 1999) . We have found that wild type CL100 associates with JNK in a manner independent of cisplatin treatment. The association of hVH-5 with JNK can also occur in basal conditions. By contrast, Pyst1 does not bind to any form of JNK. Previous reports indicate that binding of Pyst1 to its substrate increases 20-fold its intrinsic phosphatase activity (Camps et al., 1998; Dowd et al., 1997) . This requirement would explain the lack of eect of Pyst1 on JNK and p38 activities in our system. Other MAPK phosphatases may exist as constitutively active forms, as with MKP-5, which shows a high basal activity towards JNK and p38 (Tanoue et al., 1999) .
Although we have found that ectopic expression of CL100 and hVH-5 is capable of inhibiting cisplatin induced apoptosis it remains to be established whether CL100 plays a physiological role in regulating this process. We have previously noticed that MKP-1, the mouse CL100 homolog is dierentially regulated by cis and transplatin suggesting that it is a target that may play an important role in cisplatin mediated apoptosis. On the other hand, hVH-5 is probably a poor candidate given its restricted tissue distribution (Martell et al., 1995) . Expression of a catalytically inactive form of CL100 is able to switch the transient induction of c-Jun phosphorylation in response to transplatin into a prolonged one. Furthermore, expression of mutant CL100 enhances c-Jun-dependent transcriptional activation, suggesting that complex formation between the catalytically inactive CL100 and phospho-JNK does not compromise JNK activity on its substrates. Similar experiments have been performed with a Cys to Ser mutant of Pyst1 and it has been shown that the kinase in this complex is still able to phosphorylate target proteins (Brunet et al., 1999) . We have reported that pre-treatment of cells with orthovanadate (a tyrosine phosphatase inhibitor) sensitizes cells to cis and transplatin treatment probably by modulating an endogenous tyrosine phosphatase activity (SaÂ nchez-PeÂ rez et al., 1998). The fact that expression of the mutant CL100 (C258A) produces a similar eect suggests that the mutant gene is acting as a dominant negative for the endogenous CL100. The speci®city of CL100 in vivo for JNK is high since expression of CL100 (C258A) does not seem to regulate the activity of p38 or ERK in response to cisplatin or EGF respectively. This result further supports the role of CL100 in controlling the kinetics of JNK activation after treatment with both platinum isomers, although experiments with dierent tumor derived cell lines should be done to con®rm how general this mechanism of regulation is.
MKP-1 levels are upregulated in response to DNA damage (Keyse and Emslie, 1992) and by diverse stress stimuli such as hypoxia (Laderoute et al., 1999) . On the other hand, upregulation of both MKP-1 mRNA and protein levels has been detected in samples of early stage carcinomas and in various stages of breast and prostate carcinoma (Leav et al., 1996; Loda et al., 1996; Magi-Galluzzi et al., 1997 . Finally, overexpression of MKP-1 induces resistance to Fasligand triggered apoptosis in human prostate cancer cells (Srikanth et al., 1999) . All these ®ndings together with our own results support the hypothesis that upregulation of CL100 levels could result in an increase in resistance to chemotherapy in various human tumors. Our results also suggest that CL100 is a good target that may be used to optimize cisplatin therapy by inhibition of its endogenous phosphatase activity.
Materials and methods

Cell lines, culture conditions and reagents
Pam212, Bosc23 and human embryonic kidney 293T cells were cultured in Dulbecco's modi®ed Eagle's medium containing 4.5 gr/lt glucose and supplemented with 10% fetal calf serum and 1 mM L-glutamine. Cells were cultured at a density of 10 6 cell by 100 mm plate. For cisplatin treatment cells were cultured with medium containing 0.5% FBS for 24 h, then the medium was removed and cells were treated with the corresponding dose of cisplatin. Cisplatin was prepared in distilled water and added to the cells at 80% con¯uence. 293T-C258A cells were obtained by cotransfecting 293T cells with the myc-tagged CL100 (C258A) expression vector and pPUR plasmid (Clontech) by the calcium phosphate method and selection of stable transfectants by puromycin resistance. Pam212-CL100 or Pam212-C258A cells were selected with G-418 after injection with the pLXSN (Clontech) derived retroviruses.
Reporter plasmids and expression vectors
pGST-Jun (1 ± 79) and pGST-ATF-2 were obtained from Silvio Gutkind (Coso et al., 1995; Teramoto et al., 1996) . Plasmids pSG5-Myc-CL100, pSG5-Myc-Pyst1 and pSG5-Myc-hVH-5 contains the c-myc 9E10 epitope linked to the corresponding gene and were obtained by subcloning between EcoRI and BamHI sites of the pSG5 eukaryotic expression vector (Stratagene). CL100 (C258A) was obtained by Sitedirected mutagenesis using the QuickChange site-directed mutagenesis kit (Stratagene), following manufacturer's instructions. Mutagenic oligonucleotide was as follows (sense strand shown; the substituted oligonucleotides are underlined): C258A 5'-GGGTGTTTGTCCACGCCCAGGCAGG-CATTTCC-3'. Mutation was veri®ed by sequencing the entire cDNA. Plasmids pLXSN-Myc-CL100 and pLXSN-Myc-CL100 (C258A) were obtained by subcloning the EcoRI and BamHI inserts of the pSG5 corresponding expression vector into the sites of the pLXSN vector (Clontech). GAL4c-Jun (1 ± 223), 56GAL4-LUC reporter and the MEKK1 expression vectors were obtained from Michael Karin. (Perona et al., 1997) .
Transfections, infections and gene expression analysis
293T cells were plated 24 h before transfection at a density of 3610 5 cells/60 mm plate as previously described (Perona et al., 1997) and co-transfected with the plasmids pCMVbgalactosidase and plasmids encoding for pSG5 or the derived vectors containing the CL100, hVH-5 or Pyst1 cDNAs. For kinase assays, cells were incubated in 0.5% FCS for 24 h and treated with cisplatin for 6 h. Eciency of transfection was estimated by transfecting parallel plates and staining for bgalactosidase. Routinely an 80% eciency was obtained. Bosc23 cells (2610 6 cells/60 mm plate) were transfected with 3 mg of the pLXSN empty or derived vectors as described (Perona et al., 1997) . After 48 h supernatant viruses were used to infect Pam212 cells (1.5610 6 cells/100 mm plate). Cells were selected with G-418 and subjected to the dierent treatments. For assay for c-Jun transcriptional activity we utilized a mammalian two-hybrid system. Cells were cotransfected with 0.5 mg of 56GAL4-LUC reporter, and 0.5 mg of GAL4-c-Jun (1 ± 223) fusion protein containing the c-Jun activation domain. Six hours after transfection, cells were washed twice in 16PBS, and allowed to grow in serumfree medium for 24 h. Cells were then harvested and lysed using Luciferase Lysis Buer (Promega). The lysate was centrifuged at 10 000 g and the supernatant was assayed for luciferase activity using a Berthold luminometer. Results are expressed as fold induction considering 100 the luciferase activity for the cells transfected with MEKKI.
Extract preparation and solid phase kinase assays
Whole cell extracts preparations for JNK assays were done as described (SaÂ nchez-PeÂ rez et al., 1998). Reactions were done in the presence of 1 mCi of [g-32 P]ATP in 30 ml of kinase buer. The kinase reaction was performed at 308C for 30 min and stopped with the addition of SDS sample buer. For p38 MAPK assays cells were prepared as described (SaÂ nchezPeÂ rez et al., 1999). p38MAPK was immunoprecipitated for 3 h at 48C with constant agitation with speci®c antibody/ protein A-Sepharose (Santa Cruz-Pharmacia). Immunoprecipitates were washed twice with lysis buer and kinase assay buer prior to kinase assays (SaÂ nchez-PeÂ rez et al., 1999). In vitro kinase assays were performed on immunoprecipitates resuspended in 30 ml of assay buer and 2 mg of GST-ATF2. Reactions were initiated by addition of 20 mM ATP containing 5 mCi [g-32 P]ATP. After 30 min at 308C, reactions were stopped by boiling with sample buer. When SB203580 was used, it was added to the immunoprecipitated p38, prior to the kinase reaction. The reaction mixtures were resolved by SDS-polyacrylamide gel electrophoresis analysis. Gels were stained and the amount of peptide in each lane determined in order to correct for dierences in the substrate concentration. The amount of radioactivity incorporated in each lane was determined with an instantimager and corrected against the amount of peptide in each lane.
Apoptosis and cell viability assays
For DNA fragmentation studies, cells (1610 6 ) were harvested and lysed as described (Esteve et al., 1998) . DNA was resolved in 1.8% agarose gels containing ethidium bromide in 16TBE and was visualized by UV illumination. Apoptotic cells were identi®ed by ®xing cells in 3.7% formaldehyde and staining with 0.1 mg/ml of DAPI and analysed by¯uorescence microscopy with an ultraviolet ®lter. The percentage of apoptotic cells was determined by counting the amount of cells with typical nuclear apoptotic morphology among the total number of cells. Cell viability was determined using a crystal violet based staining method as previously described (SaÂ nchez-PeÂ rez et al., 1998).
Immunoblotting and immunoprecipitations
For Western blot analysis, whole cells lysates were prepared in lysis buer (25 mM HEPES [pH 7.5], 300 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM dithiothreitol, 20 mM b-glycerophosphate, 0.1 mM Na 3 VO 4 , 0.5 mM PMSF, 1 mg/ml leupeptin, 0.5 mg/ml pepstatin and aprotinin). 30 mg of total cellular protein were subjected to SDS-polyacrilamide gel electrophoresis, transferred to PVDF (Immobilon-P, Millipore), and incubated with a 1 : 1000 dilution of anti-myc antibody. Phosphorylated forms of cJun, p38 and p44/42 MAPK were detected with anti phospho c-Jun, antiphospho p38 and anti-phospho p44/p42 MAPK antibodies respectively. Immunocomplexes were visualized by enhanced chemiluminescence detection (Amersham) using a Goat anti-rabbit or mouse IgG (HRP) conjugated from BioRad. For coimmunoprecipitation studies 293T cells transfected with either myc-tagged CL100, Pyst1 or hVH-5 and HA-JNK1, were lysed in the following buers: 25 mM HEPES pH 7.7, 300 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5% TRITON X-100, 2 mM DTT, 1 mM PMSF for CL100 transfected cells or 20 mM HEPES pH 8.0, 10 mM KCL, 0.15 mM spermidine, 1 mM DTT, 0.5% NP-40, 0.5 mM PMSF, 1 mg/ml leupeptin, 0.5 mg/ml pepstatin and aprotinin for cells transfected with Pyst1 and hVH-5. The antibody Ab 12CA5 (Boehringer-Mannheim) was added for immunoprecipitation followed by protein-G Sepharose. Precipitates were washed with lysis buer, resolved by SDS ± PAGE and transferred to PVDF before immunoblotting using anti-myc antibody. Immunocomplexes were visualized by chemiluminescence analysis (ECL).
Antibodies anti p38 (aa 341 ± 360), anti c-jun (KM-1), anti c-myc (C-terminal 9E10 tag), anti ERK2 were from Santa Cruz Biotechnology. Phospho-p38 MAP Kinase (Thr180/ Tyr182) antibody from New England Biolabs and antiPhospho-p44/42 MAP Kinase (Thr202/Tyr204) E10 monoclonal antibody from New England Biolabs.
